Most biotech breakthroughs don’t fail in the lab.
They fail when science meets manufacturing reality.
And by the time this bottleneck appears, tens of millions are already sunk.

This episode examines the most under-discussed failure point in modern biotech: the gap between scientific discovery and scalable, usable healthcare solutions.

While science has never been stronger—and big pharma excels at market access—companies that can translate breakthrough biology into industrialized medicines remain rare. Manufacturing, regulation, clinical design, usability for patients and physicians, and global scalability still form a narrow bottleneck where most value is lost.

In this conversation, Björn Cochlovius, CEO of Eleva, explains why so many promising biologics fail late—and how Eleva deliberately built a platform designed not to replace existing systems, but to rescue projects that would otherwise be abandoned.

Drawing on decades across immunology, biotech leadership, and translational medicine, Björn offers a grounded, operator-level view on what it actually takes to move from elegant science to real-world impact.

As he puts it:
(00:28:59) “In biotech, courageous decisions often look wrong—until years later.”

This discussion goes beyond manufacturing alone. It explores why turning scientific concepts into ready-to-deploy healthcare solutions—complete with clinical data, regulatory pathways, scalable production, and high usability—remains one of the hardest industrial challenges of our time.

What You’ll Learn in This Episode
1️⃣ Why biologics often fail late—after science already worked
2️⃣ Why manufacturing is only one part of a deeper industrial bottleneck
3️⃣ How Eleva approaches risk when others walk away
4️⃣ Why courage, not optimization, drives breakthrough biotech decisions
5️⃣ How AI supports discovery—without replacing human judgment
6️⃣ What Europe gets right—and still gets wrong—about scaling biotech

🧭 Selected Timestamps
(00:03:00) Why biotech breakthroughs fail at manufacturing
(00:07:18) Three takeaways for founders and investors short on time
(00:08:36) Why biologics production breaks at scale
(00:11:41) Salvaging proteins that standard systems cannot produce
(00:15:27) The hidden opportunity in “failed” proteins
(00:17:21) Why late-stage manufacturing failure destroys value
(00:19:35) Why Eleva builds its own pipeline, not just a platform
(00:22:46) Glycosylation as a source of better efficacy
(00:27:03) Courageous decisions when everyone else has failed
(00:30:04) Risk management through parallel scientific bets
(00:32:08) Why similar proteins behave differently in patients
(00:37:08) AI as a tool, not a replacement for human judgment
(00:41:02) Why humans must remain accountable in drug discovery
(00:44:25) The tension between basic research and development
(00:46:01) Managing the handover between scientific universes
(00:50:38) The CEO’s real job: building teams smarter than yourself
(00:53:11) Leadership humility and protecting the team
(00:56:11) How leaders recharge under long-term pressure
(00:59:13) Europe’s biotech bottleneck and why there is still hope
(01:02:20) Final reflection: turning science into systems that scale

🎙️ Beginner’s Mind
Top 10% globally. Conversations for founders, investors, executives, and policymakers shaping the future of biotech, deep tech, and healthcare.

Follow the show for more episodes where science meets s

Send a text

Support the show

Join the Podcast Newsletter: Link